UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Chest, ISSN 0012-3692, 08/2017, Volume 152, Issue 2, pp. 424 - 434
atypical hemolytic uremic syndrome | intensive care | thrombocytopenia | organ failure | eculizumab | thrombotic microangiopathy | plasma exchange | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Diagnosis, Differential | Atypical Hemolytic Uremic Syndrome - therapy | Critical Care - standards | Standard of Care | Humans | Atypical Hemolytic Uremic Syndrome - etiology | Genetic Testing - methods | ADAMTS13 Protein - metabolism | Complement System Proteins - metabolism | Plasma Exchange - methods | Adult | Atypical Hemolytic Uremic Syndrome - diagnosis | Quality of Health Care - standards | Intensive care units | Services | Physiology, Pathological | Care and treatment | Usage | Critically ill | Diagnosis | Health aspects | Hemolytic-uremic syndrome | Index Medicus | Abridged Index Medicus
Journal Article
Kidney international, ISSN 0085-2538, 03/2017, Volume 91, Issue 3, pp. 539 - 551
anti-complement therapies | atypical hemolytic uremic syndrome | kidney disease | complement | glomerulonephritis | C3 glomerulopathy | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Genetic Predisposition to Disease | Kidney - drug effects | Kidney - pathology | Humans | Risk Factors | Glomerulonephritis - genetics | Kidney - immunology | Glomerulonephritis - immunology | Treatment Outcome | Atypical Hemolytic Uremic Syndrome - immunology | Complement C3 - immunology | Glomerulonephritis - drug therapy | Atypical Hemolytic Uremic Syndrome - pathology | Phenotype | Animals | Glomerulonephritis - pathology | Complement Inactivating Agents - therapeutic use | Atypical Hemolytic Uremic Syndrome - drug therapy | Atypical Hemolytic Uremic Syndrome - genetics | Complement C3 - genetics | Complement Activation - drug effects | Index Medicus | Life Sciences | Human health and pathology | Urology and Nephrology
Journal Article
American journal of kidney diseases, ISSN 0272-6386, 2014, Volume 64, Issue 4, pp. 633 - 637
Nephrology | Atypical hemolytic uremic syndrome | discontinuation | eculizumab | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Hematologic and hematopoietic diseases | Nephropathies. Renovascular diseases. Renal failure | Renal failure | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Platelet diseases and coagulopathies | Atypical Hemolytic Uremic Syndrome - economics | Recurrence | Drug-Related Side Effects and Adverse Reactions - prevention & control | Humans | Middle Aged | Child, Preschool | Cost of Illness | Infant | Male | Atypical Hemolytic Uremic Syndrome - psychology | Antibodies, Monoclonal, Humanized - economics | Antibodies, Monoclonal, Humanized - administration & dosage | Complement Inactivating Agents - economics | Adult | Female | Atypical Hemolytic Uremic Syndrome - diagnosis | Atypical Hemolytic Uremic Syndrome - drug therapy | Child | Complement Inactivating Agents - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug-Related Side Effects and Adverse Reactions - etiology | Treatment Outcome | Withholding Treatment | Remission Induction | Urinalysis - methods | Atypical Hemolytic Uremic Syndrome - physiopathology | Adolescent | Hemoglobinuria - etiology | Monitoring, Physiologic - methods | Quality of Life | Complement Inactivating Agents - adverse effects | Hemoglobinuria - diagnosis | Drug-Related Side Effects and Adverse Reactions - classification | Index Medicus
Journal Article
Pediatric nephrology (Berlin, West), ISSN 0931-041X, 2016, Volume 31, Issue 1, pp. 15 - 39
Pediatrics | Thrombotic microangiopathy | Nephrology | Hemolytic uremic syndrome | Complement | Urology | Plasma exchange | Plasma infusion | Medicine & Public Health | Anti-factor H antibody | Combined liver–kidney transplantation | Atypical hemolytic uremic syndrome | Eculizumab | Children | Kidney transplantation | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Predictive Value of Tests | Liver Transplantation | Age Factors | Humans | Monitoring, Immunologic | Child, Preschool | Infant | Atypical Hemolytic Uremic Syndrome - immunology | Nephrology - standards | Plasma Exchange | Patient Selection | Atypical Hemolytic Uremic Syndrome - diagnosis | Child | Complement Activation - drug effects | Infant, Newborn | Antibodies, Monoclonal, Humanized - therapeutic use | Atypical Hemolytic Uremic Syndrome - therapy | Risk Factors | Atypical Hemolytic Uremic Syndrome - epidemiology | Cooperative Behavior | Treatment Outcome | Combined Modality Therapy | International Cooperation | Kidney Transplantation | Consensus | Adolescent | Drug Monitoring | Immunologic Factors - therapeutic use | Care and treatment | Hemolytic-uremic syndrome | Research | Index Medicus | Life Sciences | Human health and pathology | Plasma | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Pediatrik | Klinisk medicin | Clinical Medicine | Hemolytic | Combined liver-kidney transplantation | infusion | uremic syndrome | Urology and Nephrology
Journal Article
Blood, ISSN 0006-4971, 05/2017, Volume 129, Issue 21, pp. 2847 - 2856
Life Sciences & Biomedicine | Hematology | Science & Technology | Hemolysis | Atypical Hemolytic Uremic Syndrome - therapy | Endothelial Cells - metabolism | Humans | Vitamin B 12 - blood | Diacylglycerol Kinase - genetics | Atypical Hemolytic Uremic Syndrome - pathology | Complement Activation - genetics | Thrombosis - pathology | Diacylglycerol Kinase - blood | Platelet Activation | Thrombosis - genetics | Thrombosis - blood | Endothelial Cells - pathology | Atypical Hemolytic Uremic Syndrome - genetics | Thrombosis - therapy | Atypical Hemolytic Uremic Syndrome - blood | Index Medicus | Abridged Index Medicus | 100 | 101 | Review Series | Clinical Platelet Disorders
Journal Article